

Investigation of the reasons for delayed presentation in proliferative diabetic retinopathy patients

Meng Zhao^{1¶}, Aman Chandra^{2&}, Lin Liu^{1&}, Lin Zhang^{3&}, Jun Xu^{1&}, Jipeng Li^{1¶*}

¹ Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing Tongren Hospital, Capital Medical University. No1. Dongjiaominxiang street, Dongcheng District, Beijing, 100730, China.

² Mid & South Essex NHS Foundation Trust (Southend University Hospital) Prittlewell Chase Essex SS00RY, UK; Anglia Ruskin University, Cambridge, UK.

³ Endocrinology, Beijing Tongren Hospital, Capital Medical University. No1. Dongjiaominxiang street, Dongcheng District, Beijing, 100730, China.

* Jipeng Li, Jun Xu and Meng Zhao are Ph.D degree

* Correspondence:

Corresponding Author: Jipeng Li

E-mail: jipeng2004@sina.com

¶ These authors contributed equally to this work.

19 Abstract

20 **Aim:** To investigate reasons for delayed presentation in patients with proliferative
21 diabetic retinopathy (PDR).

22 **Methods:** A questionnaire was designed to investigate consecutive PDR patients with
23 delayed presentation who visited our center between January 2021 and December
24 2021. The questionnaire was divided into four sections: knowledge regarding diabetic
25 retinopathy (DR), attitude toward DR treatment, difficulties adhering to follow-up
26 plans, and medical care. The systemic disease status and severity of DR were
27 recorded. Logistic analysis was undertaken to investigate DR treatment refusal and
28 delay factors.

29 **Results:** A total of 157 patients were included in this study, with an average age of
30 50.0 ± 11.6 years. The overall glycemic control was poor, with a median glycated
31 hemoglobin level (HbA1c) of 7.8% (IQR 2.5%). Among the 157 eyes, most required
32 vitrectomy intervention (144, 91.7%); 17 developed neovascular glaucoma (NVG),
33 while only 13 required additional photocoagulation. Among the 36 patients with
34 undiagnosed DM, the reason for delayed DR presentation was a lack of awareness of
35 DM status among these patients (36 cases, 100.0%). Most of the patients with a known
36 history of DM exhibited inadequate DR knowledge (29, 24.0%), believed their good
37 visual acuity did not require DR screening (98, 81.0%), and had poorly controlled
38 diabetes (113, 93.3%). Factors related to refusing DR treatment were patients with an
39 inability to receive regular diabetes treatment in internal medicine clinics (OR 6.78,

40 95% CI 1.73-26.59, $p=0.006$), patients who could not tolerate discomfort during
 41 ophthalmic examination and treatment (OR 15.15, 95% CI 2.70-83.33, $p<0.001$), and
 42 patients who did not have any retinal abnormalities detected and were not informed
 43 about the need for regular screening (OR 2.05, 95% CI 1.36-3.09, $p<0.001$).
 44 **Conclusions:** This study investigated the factors contributing to delayed presentation
 45 among patients with PDR. Many individuals in the delayed population were found to
 46 have undiagnosed DM. Among patients already aware of their DM status, reasons for
 47 delay included insufficient knowledge about DR, negative attitudes toward screening
 48 and treatment, and difficulties seeking medical care in real-life situations. Furthermore,
 49 there needed to be more improvements in the detection, treatment, and follow-up of
 50 DR by internal medicine practitioners and ophthalmologists.

51

52 Introduction :

53 Diabetic retinopathy (DR), one of the complications of diabetes, is also the leading
 54 cause of blindness in the working-age population ^[1]. Early detection and prompt
 55 treatment of PDR play a crucial role in reducing the risk of diabetes-related blindness
 56 ^[2, 3]. In countries implementing comprehensive screening programs for diabetic
 57 retinopathy, the annual incidence of blindness resulting from diabetic retinopathy has
 58 declined ^[4, 5].

59 However, despite the availability of national DR screening in some countries, many
 60 patients still do not receive timely treatment. This issue is not exclusive to specific
 61 regions, as highlighted by a national survey that revealed alarming statistics. A survey
 62 found that 70.1% of DR patients identified through retinal photography were unaware
 63 of their DR condition, while 23.1% of patients with known diabetes were unaware of
 64 their DM status ^[6]. In China, the lack of a national DR screening program and data on
 65 delayed DR presentation further exacerbates the problem. However, the increasing
 66 number of cases of DR-related blindness in the country indicates a pressing need for
 67 prompt action. Between 1999 and 2019, the annual incidence rate of DR-related
 68 blindness in China skyrocketed from 0.06 to 0.23 cases per million population, and the
 69 rate of visual impairment rose from 0.3 to 0.86 cases per million population ^[7].

70 Examining regional data sheds further light on the extent of the issue. For instance, a
 71 survey conducted among elderly residents in Beijing communities discovered that
 72 87% of patients with DR were unaware of their condition. Moreover, only 28% of

73 diabetic patients had undergone DR screening within the past year [8]. Similarly, an
74 epidemiological survey conducted in rural northern China revealed that 12.1% of
75 known diabetic patients had vision-threatening DR but had not received the necessary
76 treatment [9]. These regional findings emphasize a significant delay in diagnosing and
77 treating PDR within the diabetic population in China.

78 Various factors contribute to the delay in the diagnosis and treatment of DR. In
79 countries where national DR screening programs have been implemented, research
80 indicates that reasons for the patient delay or nonparticipation in screening include
81 insufficient social support [8], poor patient compliance [8], inadequate awareness of
82 DR [8], lack of DR-related visual symptoms [9], limited opportunities for dilated fundus
83 examination [9], restrictions on seeking medical care due to systemic diseases [10],
84 economic factors [11], racial differences [12] pain during treatment [15], and inability to
85 achieve expected visual outcomes [13, 14].

86 The prevalence of diabetes among Chinese patients has increased annually, from
87 10.9% in 2013 to 12.4% in 2018 [18]. Investigating the reason for the delayed
88 presentation of PDR is crucial for preventing DR-related blindness.

89 Therefore, we planned to study a group of PDR patients who had not received timely
90 treatment by using a questionnaire survey to investigate the reasons for delaying DR
91 diagnosis and treatment and evaluate the control of diabetes, treatment of eye diseases,
92 and severity of eye diseases. Finally, we aimed to analyze the relevant factors and
93 reasons for delaying diagnosis and treatment in these PDR patients.

94 **Material and Methods:**

95 **Questionnaire design (Appendix 1) :**

96 In this study, a questionnaire survey method was used to investigate patients. The
 97 questionnaire gathered information about the patient's medical history, medication
 98 usage for systemic diseases, and ocular treatment history. The questionnaire then
 99 focused on understanding the reasons for delayed PDR presentation among the patients
 100 and was divided into four distinct sections:

101 a. Knowledge about DR section: This part assessed the patients' understanding of DR-
 102 related knowledge before their PDR diagnosis. The assessment utilized a yes/no
 103 question format to evaluate the patients' knowledge.

104 b. Attitude toward DR treatment section: This section aimed to gain insights into the
 105 patients' attitudes toward the diagnosis and treatment of DR. It also aimed to identify
 106 subjective reasons for treatment delay by providing a list of various reasons for patients
 107 to choose from. Additionally, patients were asked whether they had ever refused DR
 108 treatment.

109 c. Difficulties in real-life section: This section investigated the social, economic, and
 110 systemic factors that patients believed could impact their willingness to seek DR
 111 diagnosis and treatment. It included questions related to insurance coverage, financial
 112 income situation, level of family support, and whether the patients were influenced by
 113 factors such as work, caregiving responsibilities, or other systemic diseases. Multiple-
 114 choice selection was utilized in this section.

d. Medical processes section: This section explored the patients' experiences with different medical processes, explicitly focusing on interactions with internal medicine physicians and ophthalmologists. It included inquiries about whether the internal medicine physicians or ophthalmologists provided DR education and informed their patients about the importance of regular fundus examinations or check-ups.

By structuring the questionnaire into these four sections, the study aimed to comprehensively investigate patients' knowledge, attitudes, obstacles, and experiences with medical processes related to DR diagnosis and treatment.

Cross-sectional survey:

The population to be surveyed in this study consisted of consecutive patients diagnosed with PDR during outpatient visits to our hospital between January 2021 and December 2021 who did not receive timely treatment. The study followed the tenets of the Declaration of Helsinki and the protocol and was approved by the Institutional Review Board of Beijing Tongren Hospital. Patients were required to sign an informed consent form and written informed consent was obtained from each participant prior to commencing the survey.

Inclusion criteria: 1) patients had to be between 18 and 70 years of age; 2) patients must have been diagnosed with PDR requiring photocoagulation or vitrectomy in at least one eye; 3) patients had to show a delayed PDR presentation, defined as those who were diagnosed with PDR but did not receive treatment during their initial outpatient visit or those who received treatment but did not undergo timely follow-up, failing to

136 detect disease progression; 4) patients must have completed all laboratory tests
137 (including routine blood, urine, and renal function tests) or have had a precise diagnosis
138 of systemic complications; 5) patients must have completed the questionnaire survey;
139 6) patients must have agreed to participate in the study.

140 Exclusion criteria: 1) patients with severe vitreous hemorrhage (VH) for which it
141 could not be determined if PDR was the cause; 2) patients in whom both eyes had
142 undergone vitrectomy due to PDR, making it impossible to determine if PDR was
143 delayed before the surgery; 3) patients who currently did not require laser or PPV
144 surgery but only needed close follow-up observation; 4) patients who were unable to
145 complete the survey questionnaire; 5) patients with comorbidities such as glaucoma,
146 optic nerve disease, or macular detachment, as these conditions may cause irreversible
147 vision loss; 6) patients who were in lockdown during the COVID-19 pandemic in
148 Beijing and were excluded from the study due to the limited availability of appointments
149 for DR patients, which could have resulted in delays in their treatment.

150 The selected patients underwent a comprehensive ophthalmic examination, including
151 a corrected visual acuity test, intraocular pressure test, and slit-lamp assessment to
152 evaluate the presence of neovascularization of the iris (NVI) and indirect
153 ophthalmoscopy and vitrectomy if needed to determine the severity of PDR. PDR
154 patients were diagnosed as those who required only photocoagulation or required
155 vitrectomy. In addition, the presence of combined NVI or NVG was recorded.

156 The patients then completed the questionnaire survey. The general condition, overall
157 health status, and history of ocular treatment details were recorded as follows: the

diagnosis of combined hypertension; combined diabetic complications; history of participating in a DR screening program; the time between the last screening and diagnosis if they participated; the refusal of DR screening or PDR treatment recommendations; history of phacoemulsification cataract extraction, intravitreal injection (IV) of anti-vascular endothelial growth factor (VEGF) agents, or pan-retinal photocoagulation (PRP) treatment; and whether the patients were followed up on time after examinations or treatments. The results of the four-section questionnaire on reasons for delayed presentation of PDR were recorded.

The laboratory examination on HbA1C and questionnaire items on controlling blood glucose were recorded for further analysis of glucose control status. The renal function test result was recorded to determine the presence of chronic kidney disease (CKD) with impaired renal function.

Incomplete laser treatment was defined as adding 500 or more laser spots during outpatient photocoagulation or surgical procedures.

PDR patients with neovascularization elsewhere (NVE) but without high-risk PDR were only treated with PRP.

PDR that required vitrectomy was defined by the presence of any of the following conditions: 1) VH that hinders further examination of the fundus, confirmed as PDR during surgery, 2) fibrovascular membranes involving or threatening the macula or associated with recurrent vitreous hemorrhage, and 3) VH due to PDR combined with NVI or NVG.

In cases where treatment was required for both eyes, the eye with better visual acuity

and a milder disease condition was selected as the study eye.

Grouping:

The patient's acceptance of their DR diagnosis and treatment is directly related to their awareness of having DM. Therefore, there are inevitably differences in the reasons for delayed presentation, DR-related knowledge, and DM control between PDR patients with undiagnosed DM and those with a clear history of DM who did not receive timely PDR diagnosis and treatment. The former group has never received diabetes treatment before being diagnosed with PDR, while the latter often faces issues causing delays in PDR diagnosis and treatment during the DM treatment process, despite being diagnosed with diabetes early on. In the subsequent investigation of the population known to have DM, we further classified them based on the following question in the survey questionnaire: "Have you ever refused the doctor's recommendation for DR diagnosis and treatment?" This latter group was divided into a non-compliant group (refusing DR diagnosis and treatment) and a compliant group (accepting DR screening or therapy). The compliant group included patients who underwent screening but were misdiagnosed as not having PDR and patients who received photocoagulation treatment but still had worsening conditions.

1. PDR patients with undiagnosed DM: Defined as patients who sought ophthalmic care due to ocular symptoms, where retinal abnormalities were discovered, leading to a diagnosis of DR, but who had not previously undergone DM screening or treatment were unaware of having DM during initial ophthalmic consultation.

2. PDR patients with a clear history of DM at the time of PDR diagnosis: This group of patients was further divided into two subgroups:

2.1. Patients who were able to complete DR screening and treatment as required: Defined as patients who have previously undergone DR screening and treatment as instructed by their doctor before the current visit, including one of the three following conditions:

2.1.1. Patients with underdiagnosed PDR: Defined as patients with a confirmed history of DM who underwent eye DR screening within the last six months as required but had negative findings and were diagnosed with PDR during the current visit.

2.1.2. Patients with PDR progression despite previous PRP treatment: Defined as patients with a confirmed history of DM and DR who had previously undergone PRP treatment as required but whose condition progressed to the extent that extra photocoagulation or surgical treatment was needed.

2.2 Patients who refused to participate in DR screening and treatment: Defined as patients previously advised to undergo DR screening or treatment but refused.

Statistical analysis:

Statistical analysis was performed using R version 3.20 (<http://www.R-project.org>). Patient characteristics were retrieved from their medical charts and recorded in Epidata Entry Clientversion2.0.3.15 (<http://epidata.dk>). The mean and standard deviation (SD) were calculated for continuous variables with a normal distribution. The median with quartiles was calculated for continuous variables with nonnormal distribution. The t-test

222 or Mann–Whitney U test was carried out for continuous variables. The chi-square or
223 Fisher's exact test was carried out for discrete data.

224 To investigate the factors related to patients refusing to undergo DR screening or
225 treatment, two independent-sample comparisons were carried out on characteristics
226 between patients who could complete DR screening and treatment as required and
227 patients who refused to participate in DR screening and treatment. Variables with a p-
228 value less than 0.3 were further enrolled in a binary backward stepwise logistic
229 regression model. Each time, one variable was included or excluded from the model by
230 comparing the Akaike information criterion (AIC) value; the model with the lowest AIC
231 was chosen.

232 **Results:**

233 **General Characteristics :**

234 A total of 157 patients, with a mean age of 50.0 ± 11.6 years and including 84 male
235 patients (53.5%), were included in this study. The overall glycemic control was poor,
236 with a median HbA1c of 7.8% (IQR 2.5%).

237 Most 157 eyes (144, 91.7%) required vitrectomy intervention; 17 developed NVG,
238 while only 13 required additional PRP.

239 PDR was confirmed in most contralateral eyes (154, 98.1%), with 3 cases of blindness
240 due to trauma. Most of these eyes did not receive timely and effective treatment,
241 resulting in 18 cases of blindness due to PDR, five patients treated with vitrectomy, 42

242 cases treated with PRP, and 10 cases treated with intravitreal injection (IV) of anti-
243 vascular endothelial growth factor (VEGF) agents (details in Table 1).

244 **Table 1 Characteristics of Diabetic patients in different groups**

	Patients with undiagno sed DM (36)	Patients with a history of DM (121)		
		Patients who refused to participate in DR screening and treatment (75)	Patients who were able to complete DR screening and treatment as required	
			underdiagnos ed PDR (30)	Progressed after PRP (16)
age (y, mean±S D)	46.3±11.0	51.6±11.0	47.5±11.8	54.9±13.3
DM duration (y, median, IQR)	0.6, 1.1	13.0, 6.5	15,7.8	20, 4.5
HbA1c (%, IQR)	7.2, 2.5	7.6, 2.6	8.6,2.7	7.5, 2.1
herb	2	2	1	1

without				
other				
medicati				
on (n)				
HTN (n)	25	35	18	9
CKD (n)	11	17	20	5
coronary	9	10	9	4
heart				
disease				
(n)				
stroke (n)	3	6	5	3
Ocular	3.5, 9.3	3.0, 7.0	4.0, 4.0	4.5, 10
symptom				
(m,				
median,				
IQR)				
Cataract	6	1	1	0
extractio				
n without				

DR				
screening				
(n)				
IV-anti	3	4	3	2
VEGF				
(n)				
incomplete PRP	6	7	5	7
(n)				
complete PRP (n)	2	4	2	3
Further treatment				
required PRP (n)	3	6	1	3
required vitrectomy without NVG (n)	30	42	27	12
required vitrectomy	3	7	2	1

SD: y with
 standard NVG (n)

deviation, IQR: interquartile range, HbA1c: glycated form of hemoglobin, HTN:
 hypertension, CKD: chronic kidney disease, IV: intravitreal injection, VEGF: vascular
 endothelial growth factor, PRP: pan retinal photocoagulation, NVG: neovascular
 glaucoma

Patient-related reasons for delayed presentation :

Patients with undiagnosed DM at the diagnosis of PDR:

We identified 36 patients who were unaware of their DM diagnosis at the time of
 PDR diagnosis. The primary reason for delayed DR presentation was that these patients
 were unaware they had DM (36 cases, 100.0%). Additionally, some patients believed
 that ophthalmic examination was only necessary when visual acuity significantly
 declined or had a noticeable impact on their daily lives (14 cases, 38.9%). Furthermore,
 a few patients believed traditional Chinese herbal therapy could cure DM and did not
 undergo systematic evaluation even after receiving suggestions to rule out DM (4 cases,
 11.2%). Notably, 14 (38.9%) did not have medical insurance, seven (19.4%) had
 economic difficulties, six (16.7%) had caregiving responsibilities, five (13.9%) had
 trouble taking time off from work, and 5 (13.9%) had concurrent management of other
 systemic diseases. These factors were identified as contributing to delayed medical

attention. None of the patients had undergone a physical examination in the past year. Due to patients' lack of awareness of their DM diagnosis, we did not investigate their compliance with blood glucose control and knowledge of DR.

Patients with a clear history of DM at the diagnosis of PDR:

We surveyed 121 PDR patients with a known history of diabetes to explore the reasons and personal factors contributing to their delay in DR treatment. The survey included patients' acknowledgment of DR, compliance with DM management, and attitudes toward DR diagnosis and treatment. Some patients were not opposed to DR treatment but had other issues, while others directly resisted DR treatment. We conducted separate investigations for these two groups.

First, we identified common issues among patients with a known history of DM who experienced delays in PDR diagnosis and treatment:

In terms of DR awareness, the patients generally exhibited inadequate knowledge. Only 29 (24.0%) individuals knew that diabetic patients require regular DR screening, and only 33 (27.3%) knew that untreated DR could lead to blindness.

In terms of behavior, patients attributed the primary reason for the delay to their excellent visual acuity, leading them to believe that DR screening was unnecessary. Ninety-eight (81.0%) patients thought their good visual acuity was the main reason for delaying DR diagnosis and treatment.

Regarding compliance with DM management, most patients (113/121, 93.3%) reported regular use of diabetic medication, but their glycemic control was poor. Among

286 them, 22 patients (18.2%) had an HbA1c level above 6.5% at their visit.

287 Furthermore, we revealed the characteristics of patients who refused DR screening or
288 treatment and the reasons for the refusal.

289 The two groups of patients showed similar levels of DR awareness in the survey
290 regarding reasons for delay ($p=0.41$, $p=0.83$), and there were no significant differences
291 in social support ($p=0.98$) or insurance coverage ($p=0.99$).

292 Compared to diabetic patients who did not refuse the recommended DR screening
293 and treatment, those who refused exhibited the following characteristics: a lower
294 proportion of regular visits to internal medicine clinics (43/75, 42/46, $p<0.001$), a
295 shorter duration of diabetes (13, 16, $p=0.005$), a higher proportion of patients with no
296 abnormalities detected during screening but no regular follow-up recommended (49/75,
297 14/46, $p<0.001$), and a lower proportion of patients able to tolerate discomfort during
298 DR examination or treatment (17/75, 3/46, $p=0.02$). Furthermore, logistic regression
299 analysis revealed three factors associated with the refusal of DR diagnosis and treatment:
300 A. Inability to receive regular diabetes treatment in internal medicine clinics (OR 6.78,
301 95% CI 1.73-26.59, $p=0.006$),
302 B. Inability to tolerate the discomfort during ophthalmic examination and treatment
303 (OR 15.15, 95% CI 2.70-83.33, $p<0.001$),
304 C. Patients who did not detect any retinal abnormalities and were not informed about
305 the need for regular screening (OR 2.05, 95% CI 1.36-3.09, $p<0.001$) (AIC=118.88,
306 AUC=0.861).

307 **Patient-perceived reasons for delayed presentation related to medical, family, and** 308 **social aspects:**

309 After investigating the reasons for the delay as perceived by themselves, we further
310 examined the difficulties that could lead to delays, including financial problems, work
311 distractions, family caregiving responsibilities, inability to seek medical attention
312 independently, and the need to treat other systemic diseases. The ranking of these
313 reasons varied among different patient groups (Figure 1).

- 314 1. For individuals who were unaware of their DM diagnosis at the time of PDR
315 diagnosis, the factors influencing their DR treatment were as follows: financial
316 difficulties (16.7%), being occupied by work (16.7%), family caregiving
317 responsibilities (14.9%), and the need for treatment of other systemic diseases
318 (11.9%).
- 319 2. For the PDR patients who refused DR treatment suggestion, the factors influencing
320 their participation in DR screening were as follows: the need for treatment of other
321 systemic diseases (16.0%), being occupied by work (12.0%), lack of accompanying
322 during medical visits (8.0%), and financial difficulties (5.3%).
- 323 3. For the PDR patients with underdiagnosed DR, the factors influencing their situation
324 were as follows: the need for treatment of other systemic diseases (26.7%), being
325 occupied by work (13.3%), financial difficulties (10.0%), and lack of accompanying
326 during medical visits (2.9%).
- 327 4. For the PDR patient experiencing disease progression after PRP treatment, the

factors influencing their situation were as follows: the need for treatment of other systemic diseases (31.3%), lack of accompanying during medical visits (25%), financial difficulties (25%) and being occupied by work (30%).

Figure 1 The radar chat for the patient-perceived reasons for delayed presentation among different groups.

Deficiencies in the healthcare services in response to the delayed presentation:

In addition to the patients and their support system, we identified deficiencies in DM screening, the management of diabetic patients by internal medicine physicians, and the treatment for DR provided by ophthalmologists, all contributing to delays in DR management.

Inadequate DM screening among the general population:

Our study identified 36 patients diagnosed with DM only when PDR was detected in the ophthalmology clinic. These patients had not undergone DM screening previously. For them, the main issue contributing to treatment delay is why DM was not detected promptly.

Issues with internal medicine physicians in DR management:

After being diagnosed with DM, patients most frequently interact with internal

347 medicine physicians. Among patients with a known history of DM but who
348 experienced treatment delays, we identified problems related to guidance on regular
349 visit, education on DR, and the sensitivity of DR screening by internal medicine
350 physicians.

351 Internal medicine physicians did not emphasize the importance of regular follow-up
352 visits for DM patients. Our study found that among individuals with known history of
353 DM, 36 patients (29.75%) did not have regular visits to internal medicine physicians.
354 Furthermore, the proportion of patients who did not have regular visits and underwent
355 DR screening was lower. This was evident in the following aspects: 1) a lower
356 proportion of patients who received information from internal medicine physicians
357 about the potential blindness caused by DR, compared to those with regular visits
358 (4/36, 29/85, $p=0.01$); 2) a lower proportion of patients with irregular visits who
359 underwent DR screening, compared to those with regular visits (11/36, 67/85, $p=0.01$).

360 We found a lack of DR education among internal medicine physicians. Among the
361 121 patients known to have DM, only 18 individuals (14.9%) received DR education
362 from internal medicine physicians, which was significantly lower than the proportion
363 of patients receiving DR education from ophthalmologists (18/121 vs 62/121,
364 $p<0.001$). Even among the 85 patients with regular visits, only 25 individuals were
365 aware of the importance of regular fundus examinations. The majority of patients
366 obtained knowledge about DR through ophthalmic DR screening, and those who
367 underwent DR screening had better awareness of DR compared to those who did not
368 undergo screening (DR screening necessary: 40/66 vs 81/91, $p<0.001$; DR can cause

369 blindness: 46/66 vs 80/91, $p=0.008$).

370 During the initial visit for DM, internal medicine physicians did not sufficiently
371 emphasize the potential for blindness due to DR and the importance of regular
372 asymptomatic DR examinations. Among the 55 patients who refused retinal screening,
373 87.3% believed that good vision meant they did not need screening, which was the
374 primary reason for their refusal. Additionally, we found that 14.5% of patients delayed
375 DR screening out of fear of detecting retinal abnormalities.

376 We observed a low sensitivity of DR screening initiated by internal medicine
377 physicians. This could lead patients to mistakenly believe that their fundus are normal
378 and overlook the importance of regular follow-up examinations. Our study identified
379 30 patients who underwent DR screening within the past six months without detecting
380 any retinal abnormalities. However, within the subsequent six months, 29 patients
381 developed PDR retinal lesions requiring surgical intervention, including two
382 individuals who developed NVG. Among them, 20 patients had undergone DR
383 screening initiated by internal medicine physicians, while ten had undergone screening
384 initiated by ophthalmologists. The rate of missed diagnosis in DR screening initiated
385 by internal medicine physicians was 20/21, significantly higher than that of
386 ophthalmologists, which was 10/45 ($p<0.001$).

387 Internal medicine physicians did not adequately emphasize the need for regular DR
388 screening when DR was not detected. Our findings demonstrated that among patients
389 who underwent initial screening without detecting DR, those who were not informed
390 about the importance of regular follow-up had fewer opportunities for PDR treatment

391 compared to those who were notified. Among the 30 patients with negative retinal
 392 findings during the initial screening, 14 individuals were not informed about the need
 393 for follow-up, and 12 were not informed by internal medicine physicians. These patients
 394 did not receive PDR treatment during the subsequent six months. On the other hand, 16
 395 patients were informed about the need for regular follow-up. During the subsequent
 396 examinations, they were diagnosed, with two individuals receiving the opportunity for
 397 complete PRP treatment and five individuals completing partial PRP treatment before
 398 the onset of vitreous hemorrhage (0/14, 7/16, $p=0.007$).

399 Our investigation revealed that 28 patients experienced delays in DR treatment due
 400 to hospitalization for systemic diseases. These patients did not receive ophthalmic
 401 consultations or treatment during their hospital stay, nor did they receive any
 402 educational information about DR from internal medicine physicians.

403 We identified 8 PDR patients who regularly sought treatment from traditional
 404 Chinese medicine (TCM) practitioners. These patients were of working age, ranging
 405 from 33 to 62 years old, with a median age of 59 (standard deviation 7.75 years).
 406 However, these patients relied solely on TCM instead of receiving systematic glucose-
 407 controlling medicine (6/8), resulting in poor blood glucose control (elevated glycated
 408 hemoglobin levels, with an average of 7.1 ± 1.1) and severe systemic complications
 409 (8/8). Prior to their diagnosis of PDR, these patients lacked awareness of DR, unaware
 410 of its potential to cause blindness and the need for regular examinations (8/8).
 411 Furthermore, none underwent ophthalmic DR screening (8/8), leading to the
 412 development of PDR complications requiring surgical intervention.

Insufficiencies in the Diagnosis, Treatment of DR by Ophthalmologists:

Ophthalmologists are responsible for treating DR, particularly in emphasizing the importance of regular follow-up for early-stage DR that does not affect vision. However, we found that DR patient education inadequately emphasizes this importance. Only 62 out of 121 patients received DR education from ophthalmologists. Additionally, a considerable proportion of patients who received DR treatment falsely believed that having good VA meant they did not require ophthalmic care and postponed seeking medical attention. This behavior was similar to that of patients who did not comply with the recommended DR treatment (39/46, 59/75, $p=0.55$).

Ophthalmologists have shown insufficient efforts in educating and encouraging patients who exhibit resistance and pain-related concerns during DR treatment. Alternatively, the understanding of patients may have needed to be improved despite information from ophthalmologists. We discovered that discomfort experienced during fundus examinations and PRP therapy became the primary reasons for delayed presentation of DR. When investigating the reasons behind delayed medical intervention among different patient groups, we found that 65% of patients who refused PDR treatment did so out of fear of pain associated with PRP therapy. Similarly, among patients who experienced disease progression after PRP treatment declined and refused to complete the treatment due to pain related to PRP therapy. Furthermore, four individuals who refused fundus examination within the group declined PRP treatment

due to discomfort. In the group where improper PRP treatment resulted in DR progression, three patients declined subsequent follow-ups due to discomfort during eye examinations post-PRP treatment. These patients exhibited insufficient awareness regarding the risk of blindness associated with DR and the necessity of regular follow-up examinations (10 patients, 50%, among those who refused treatment, and four patients, 66.7%, among those who completed treatment but did not undergo follow-up examinations). As a result, they lacked the necessary determination to overcome discomfort and complete the required examinations and treatment.

We found that ophthalmologists needed to adequately emphasize the possibility of disease progression and the importance of regular follow-up examinations after PRP treatment, as demonstrated by the patient's lack of knowledge. Among the 16 patients who completed PRP therapy, 11 were unaware of the need for regular follow-up examinations after treatment. Despite relatively stable vision in these patients (11/16), factors such as being occupied by work, systemic illnesses, family responsibilities, financial difficulties, and discomfort with examinations and PRP treatment contributed to their failure to attend follow-up appointments. As a result, ten patients experienced disease progression to a stage requiring vitrectomy.

Furthermore, we found that some ophthalmologists performed PRP treatment with inadequate coverage, leading to delays in disease management. Six patients were informed of completing PRP treatment, and their condition progressed to PDR requiring vitrectomy. However, during the surgery, it was discovered that the PRP coverage was insufficient. These patients did not attend follow-up examinations promptly after

456 completing PRP treatment.

457 Some ophthalmologists overlooked DR screening when performing cataract
 458 extraction surgery on diabetic patients. Among the ten patients who underwent cataract
 459 extraction surgery before receiving DR treatment, seven individuals with improved
 460 vision underwent no retinal screening. In comparison, only one out of the three patients
 461 whose vision did not improve underwent DR screening, leading to a missed diagnosis.
 462 The improvement in visual acuity following cataract extraction surgery may have
 463 contributed to the delay in the diagnosis and treatment of DR.

464 **Discussion:**

465 Early detection and intervention can prevent blindness caused by DR ^[4, 5], so delayed
 466 treatment may result in severe and regrettable consequences. In China, the incidence
 467 of blindness caused by DR is rapidly increasing, becoming an essential factor in the
 468 rise of the blindness rate ^[7]. The factors leading to the delayed presentation of DR in
 469 Chinese diabetic patients are complex and diverse; however, there are currently no
 470 reports on the reasons for it. Investigating the reasons for the delayed presentation of
 471 DR in diabetic patients is significant for preventing and treating blindness caused by
 472 DR.

473 **The specific DM population that the ophthalmologist should pay more attention**
 474 **to:**

475 1. Patients with poor diabetes control:

Our investigation revealed that this group of diabetic patients commonly exhibited poor blood glucose control, which may lead to rapid DR progression. Specifically, we observed that patients had elevated HbA1c (with a median of 7.8%), and only 18.2% had their HbA1c controlled below 6.5% at their visit. It is established that poor blood glucose control is associated with microvascular complications in diabetic patients ^[15]. Studies have shown that individuals with HbA1c between 6.5 and 6.9 have a 2.35 times higher risk of developing DR within three years than those with HbA1c between 5 and 5.4 ^[16]. Therefore, based on our inference, poor blood glucose control is an essential factor contributing to the rapid progression of DR in the population with the delayed presentation in our study. Ophthalmologists should pay special attention to and provide education specifically for this population.

2. Patients with a high possibility of refusing DR treatment:

We compared patients who refused DR treatment suggestions with those who accepted them to investigate the factors associated with refusal. Ophthalmologists should be attentive to patients with the following characteristics, as they are more likely to be less engaged in DR treatment. Targeted education and follow-up should be provided to these patients to slow the progression of DR. Patient information leaflets, or website education may also allow patients to review and revise the issues.

A. Patients who do not visit internal medicine regularly are more prone to refuse DR treatment. Compared to patients who do not visit internal medicine regularly, those who have regular visits have a 6.78 times higher chance of receiving timely DR treatment. This could be attributed to regular patients receiving more DR education

(29/85, 4/36) and more DR screening opportunities (67/85, 11/36).

B. Patients who exhibit intolerance to pain and discomfort during examinations and treatment are more likely to refuse DR treatment. The likelihood of refusing DR treatment increased by 15.15 times for patients who strongly resisted pain and discomfort compared to those who were less resistant. This resistance is particularly evident among patients who refuse DR treatment (13/20), whereas factors related to delays in PRP treatment due to hospitalization for systemic diseases accounted for only 5/20 cases. Furthermore, previous studies have shown that fear of discomfort during ophthalmic examinations is a primary reason patients refuse DR screening [10,24]. Surveys regarding satisfaction with PRP treatment indicate that insufficient knowledge about laser treatment^[17], discomfort caused by pupillary dilation^[17], pain during laser treatment^[17]^[18], and failure to achieve expected visual acuity^[13, 14] may lead to patient reluctance towards PRP treatment, thereby affecting compliance with laser treatment and subsequent follow-up examinations. The results of our study align with previous research.

C. Patients unaware of the need for regular follow-up after DR screening and with no positive DR finding were more likely to refuse visits for DR screening. Compared to patients advised of timely treatment and had DR detected during screening, those who did not receive regular follow-up advice and had no evidence of DR during screening were 2.05 times more likely to refuse DR screening or treatment. Guidelines recommend annual retinal examinations for diabetic patients without DR [3]. In our study, a group of patients (30/121) had no DR detected during their initial

screening but progressed to PDR within the following six months. Most of these patients' DR screenings were conducted by internal medicine doctors (20/30), indicating the possibility of missed diagnoses. However, these patients shared the common characteristics of a long time of poor blood glucose control, with a median HbA1c of 8.6 and a median duration of DM of 15 years. It was suggested that individuals with a long duration of DM and poor blood glucose control might experience rapid progression of DR, even if abnormalities are not initially detected. Annual follow-up examinations may delay the diagnosis, indicating the need to shorten the interval for DR screenings.

Reducing delays requires joint efforts from society and healthcare professionals:

Practical difficulties:

After investigating the self-perceived factors contributing to delays in our study, we referred to common reasons reported in previous studies, such as economic difficulties [11], lack of nearby medical facilities, other commitments, and hospitalization [8, 10], to examine the barriers identified by patients that hindered their adherence to regular DR treatment.

We identified several social factors that can influence the timely receipt of DR treatment among diabetic patients. These factors should receive greater attention and improvement in receiving similar diabetic patients in the future to provide timely DR treatment for diabetic patients.

Some low-income or uninsured patients did not have the opportunity to undergo

541 diabetes screening. Among patients unaware of their diabetes diagnosis when diagnosed
 542 with PDR, a considerable portion consisted of low-income individuals without health
 543 insurance. These patients are typically younger, with 14 (38.9%) lacking health
 544 insurance and 7 (19.4%) stating they could not seek medical care due to economic
 545 difficulties. Many patients missed medical visits due to obligations such as caring for
 546 family members or work, and these patients had not undergone regular health check-
 547 ups in the past year. Therefore, efforts should be made to enhance diabetes screening
 548 for individuals without health insurance or facing economic difficulties to identify
 549 individuals with diabetes at an early stage and facilitate subsequent DR screenings for
 550 these patients.

551 The absence of a companion may pose a barrier for diabetic patients to attend DR
 552 treatment. Patients consider the lack of a companion during medical visits a primary
 553 challenge in receiving DR treatment. This situation is particularly prominent among
 554 patients who refuse DR treatment (6/20) and those who have completed PRP treatment
 555 but have no regular follow-up examinations (4/16). PDR can impact patients'
 556 independent living abilities ^[19], causing inconvenience in their daily lives. Therefore,
 557 for diabetic patients with visual impairments, family members are encouraged to
 558 accompany them during medical visits to help provide them with more opportunities to
 559 receive DR treatment.

560 The inability to take time off from work may hinder diabetic patients from attending
 561 DR treatment. According to our research, 10.9% of patients who refuse DR screening
 562 stated that the inability to take time off work was the reason for not being able to undergo

timely screening. Similarly, 13% of patients with missed DR diagnoses and 18.7% of patients who completed PRP treatment believed that the inability to take time off work was the reason for not being able to attend scheduled DR follow-ups. It is crucial to identify their concerns about needing help to take leave during the initial consultation and provide individualized guidance and support. It is essential to be cognizant that patients with end-stage DM disease, such as PDR, are likely to have numerous medical appointments, and the impact on their work can be extensive. Physicians or ophthalmologists should provide adequate patient education to enhance treatment compliance.

Medical care:

Our investigation found that the reasons for treatment delay among patients are attributed to the patients and the factors related to the treating physicians. The treatment process for DM involves a complete chain of care, starting from the initial diagnosis of DM to DM follow-ups, to DR screening, and finally, the diagnosis and treatment of DR. However, if any link in this chain encounters issues, it can delay patient treatment. Therefore, physicians and ophthalmologists need to strengthen their attention and management at each stage of the treatment chain to ensure that patients receive timely care.

- a. There are deficiencies in the DM patient education provided by physicians and ophthalmologists, primarily regarding dispelling the misconception that regular DR screening is unnecessary as long as their vision is not deteriorating. Our research

revealed that 81.0% of delayed patients believed that good vision meant they did not need medical attention. This misconception was prevalent among patients receiving regular internal medicine care (60/85) and those undergoing ophthalmic DR treatment (59/75). It reflects a need for more emphasis on the importance of early DR screening by the physicians and ophthalmologists attending to these patients. Studies have shown that patients' understanding of the potential blindness caused by the delayed detection of DR directly influences their adherence to DR treatment [9]. Insufficient awareness of the need for DR screening and the misconception that good vision eliminates the need for ocular examinations are associated with the severity of proliferative diabetic retinopathy (PDR) when diabetic patients seek ophthalmic care [20]. Therefore, patient education for diabetic patients should focus on the importance of regular follow-ups for early DR detection, irrespective of visual symptoms. During consultations with diabetic patients, every opportunity should be seized to emphasize that early-stage DR may not affect vision, the need for regular DR screening, and the significance of early detection and treatment.

b. Some errors made by the physicians:

When diagnosing and treating systemic diseases, internal medicine physicians should also pay attention to diagnosing and treating DR. We found that 28 patients had delayed DR presentation due to treating their systemic conditions. Previous studies have indicated that hospitalization in internal medicine is a major factor contributing to delays in PRP treatment [10], which aligns with our research findings.

Therefore, while treating systemic diseases, internal medicine physicians should promptly seek ophthalmic consultations when feasible to ensure timely diagnosis and treatment of DR.

During internal medicine follow-ups for DM, attention should be given to patients with psychological issues. In this study, 14.5% of patients refused DR screening due to concerns about discovering retinal abnormalities. This reason was not mentioned in previous research. The majority of these patients do not actively seek ophthalmic screenings, even though they have some understanding of DR and its screening. They experience excessive anxiety about potential positive test results. The prevalence of depression (25%) and anxiety (13.5%) is relatively high among DR patients in our country, and social support can alleviate anxiety and depression in these patients ^[21]. Internal medicine physicians should promptly identify patients with abnormal psychological emotions and provide positive guidance, such as informing them that having DR does not inevitably lead to blindness and that timely treatment can slow down disease progression and stabilize vision. It is also essential to seek the cooperation and support of family members and encourage patients to undergo DR diagnosis and treatment.

The sensitivity of DR screenings initiated by physicians needs to be improved. In this study, physicians' missed DR diagnosis rate was 20/21, which is relatively high. Previous research has shown that the sensitivity of non-mydriatic single-field fundus photography and DR interpretation initiated by internal medicine physicians is 86.6% with a specificity of 78.6% ^[22], indicating their potential role in DR screenings.

However, our study's sensitivity of DR screenings was much lower than the above data, meaning there is still room for improvement among our physicians. Recent studies have demonstrated that fundus photography initiated by physicians and remote image reading can enhance the accuracy of DR screening [23]. Therefore, improving the sensitivity of DR screening by physicians or implementing reliable remote network image reading guidance may play a crucial role in the timely detection of DR in DM patients who do not seek ophthalmic care. Alternatively, trained nonphysician graders have been demonstrated to be highly successful. In the UK, this has reduced the impact of diabetic eye disease-related blindness [24].

Additionally, we found that among the 20 PDR patients with missed diagnoses in DR screenings initiated by physicians, 14 needed to be made aware of the need for regular follow-up visits. These patients did not pursue further ophthalmic care due to their excellent vision. It suggests that physicians and other health care professionals involved in their care needs must further strengthen patient education and urge patients to undergo ophthalmic follow-up visits.

There are also issues with TCM regarding DR screenings and patient education. We identified eight patients receiving treatment in TCM internal medicine who opted for traditional Chinese medicine instead of glycoside-controlled medicine. This resulted in poor blood sugar control (HbA1c 7.1 [1.1]), no DR screenings, and delayed treatment until severe PDR developed. Additionally, they had uncontrolled systemic complications (high rates of HTN (6/8), CKD (4/8), and a high proportion of CAD (3/8) that were not addressed by internal medicine treatment. These patients,

aged between 32 and 62, belong to the working-age population. Once life-threatening and vision-threatening complications occur, they will burden society significantly. Previous studies have shown that traditional Chinese medicine (TCM), as a benefit as an adjunct to conventional treatment for DM, including medication, exercise, and dietary control, may affect controlling HbA1c levels and improving vision [25, 26]. Therefore, it is essential to enhance the understanding of TCM physicians regarding DR screenings. When diagnosing DM, patients should be informed about the importance of medication, diet, exercise, blood sugar control, and glucose-control medicine treatments. Simultaneously, patients should be encouraged to undergo DR screenings to minimize treatment delays caused by solely focusing on vision changes.

c. The ophthalmologists should make some improvements:

Ophthalmologists' failure to remind patients who have undergone cataract extraction about the importance of DR-related fundus examination can delay treatment for diabetic patients who experience improved vision post-surgery. Ten patients with a history of cataract extraction were included in this study, of which eight did not undergo DR screening. Among these eight patients, seven reported improved vision after the surgery, and five of them did not receive a fundus examination because they believed their vision was already good. Previous research has indicated that vision improvement following cataract surgery in diabetic patients can potentially mask vision symptoms caused by DR. Additionally, cataract surgery in diabetic patients can contribute to the progression of PDR, necessitating

perioperative intravitreal anti-VEGF agents and vigilant postoperative follow-up [27, 28]. Therefore, ophthalmologists should prioritize strengthening DR screening and follow-up for diabetic patients undergoing cataract surgery. This approach is crucial to identify DR promptly and prevent further deterioration of vision due to DR.

Ophthalmologists must prioritize regular follow-ups and effectively communicate to patients undergoing PRP treatment about ongoing examinations' importance. Our study observed that 16 patients with PDR had completed PRP treatment, but their condition continued progressing. Among these patients, 11 were unaware of the necessity for regular post-PRP examinations, and ten believed that their vision had stabilized, leading them to forego further treatment. Unfortunately, this delay in disease detection hindered early intervention. Furthermore, we discovered that six patients needed complete PRP treatment and were frequently required to pay more attention to follow-up examinations. Consequently, their condition progressed, ultimately requiring vitrectomy surgery. Previous research has demonstrated that effective PRP treatment can prevent 50% of PDR progression and mitigate 50% of severe vision damage caused by PDR [29]. However, despite PRP treatment, 42% of PDR patients still experience disease progression [30]. Patients who initiate PRP treatment after experiencing vitreous hemorrhage and retinal detachment are more likely to encounter DR progression following PRP treatment [30, 31]. Therefore, for diabetic patients who have completed PRP treatment, ophthalmologists should strengthen education regarding the effectiveness of PRP treatment and stress the need for regular follow-up examinations. It is crucial to adhere to standardized PRP

treatment protocols meticulously.

Limitations:

This study is a cross-sectional survey that focused on PDR patients who delayed seeking medical treatment. The study specifically excluded patients with well-controlled glucose levels and those compliant with DR treatment, and we could not investigate the delayed presentation in those patients. Notably, this study's proportion of patients receiving intravitreal anti-VEGF agents was relatively low. Furthermore, most patients who received this treatment did so after experiencing vitreous hemorrhage or NVG. Therefore, the reasons for the delayed progression of PDR following intravitreal anti-VEGF agents remain unclear, indicating a need for further research. Additionally, it is worth mentioning that the number of patients who underwent PRP received intravitreal anti-VEGF agents or cataract surgery was relatively small. This may have resulted in a selection bias among the study population. Furthermore, regarding retinopathy assessment, this study did not include the measurement of VA. Instead, the patient's ocular condition was evaluated solely through fundus examination. Consequently, the study failed to demonstrate any visual acuity impairment within this group of patients. Regarding systemic examination, the study exclusively recorded the patient's medical history of coronary artery disease (CAD), cerebral infarction, and other diseases and the results of kidney function tests. However, urine albumin-to-creatinine ratio (ACR) examinations were not conducted, leading to a deviation in evaluating the systemic condition.

715 **Conclusions:**

716 This study investigated the factors contributing to delayed presentation among
 717 patients with PDR. A significant proportion of individuals in the delayed population
 718 were found to have undiagnosed DM. As a result, it is crucial to enhance DM
 719 screening efforts and promote education about the condition. Among patients already
 720 aware of their DM status, reasons for delay included insufficient knowledge about DR,
 721 negative attitudes towards screening and treatment, and difficulties seeking medical
 722 care in real-life situations. Furthermore, there needed to be more improvements in the
 723 detection, treatment, and follow-up of DR by both internal medicine practitioners and
 724 ophthalmologists. It is imperative to strengthen education regarding the importance of
 725 regular DR screening, especially when it still needs to impact vision. Particular
 726 attention should be given to patients with irregular visits to internal medicine
 727 specialists and those concerned about discomfort during DR treatment. Additionally,
 728 patients who undergo cataract surgery, participate in DR screening conducted by
 729 physicians, utilize traditional Chinese medicine treatments, complete PRP, and have
 730 negative screening findings should also receive regular follow-up examinations.
 731 Finally, vigilance to patients' challenges during the diagnosis and treatment process is
 732 crucial. Patients should be encouraged to cooperate and receive support from family
 733 members throughout their treatment journey.

734

735

736

737 **References:**

- 738 1. Cheung N, P Mitchell, TY Wong. Diabetic retinopathy. Lancet. 2010; 376: p. 124-
739 36.10.1016/s0140-6736(09)62124-3.
- 740 2. Lin KY, WH Hsih, YB Lin, CY Wen, TJ Chang. Update in the epidemiology, risk
741 factors, screening, and treatment of diabetic retinopathy. J Diabetes Investig.
742 2021; 12: p. 1322-1325.10.1111/jdi.13480.
- 743 3. Flaxel CJ, RA Adelman, ST Bailey, A Fawzi, JI Lim, GA Vemulakonda, et al.
744 Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020; 127: p.
745 P66-p145.10.1016/j.opthta.2019.09.025.
- 746 4. Self-reported visual impairment among persons with diagnosed diabetes ---
747 United States, 1997--2010. MMWR Morb Mortal Wkly Rep. 2011; 60: p. 1549-
748 53
- 749 5. Tracey ML, SM McHugh, AP Fitzgerald, CM Buckley, RJ Canavan, PM Kearney.
750 Trends in blindness due to diabetic retinopathy among adults aged 18-69years
751 over a decade in Ireland. Diabetes Res Clin Pract. 2016; 121: p. 1-
752 8.10.1016/j.diabres.2016.08.016.
- 753 6. Nwanyanwu K, M Nunez-Smith, TW Gardner, MM Desai. Awareness of Diabetic
754 Retinopathy: Insight From the National Health and Nutrition Examination Survey.
755 Am J Prev Med. 2021; 61: p. 900-909.10.1016/j.amepre.2021.05.018.
- 756 7. Xu T, B Wang, H Liu, H Wang, P Yin, W Dong, et al. Prevalence and causes of
757 vision loss in China from 1990 to 2019: findings from the Global Burden of

- 758 Disease Study 2019. Lancet Public Health. 2020; 5: p. e682-e691.10.1016/s2468-
759 2667(20)30254-1.
- 760 8. Kashim RM, P Newton,O Ojo. Diabetic Retinopathy Screening: A Systematic
761 Review on Patients' Non-Attendance. Int J Environ Res Public Health. 2018;
762 15.10.3390/ijerph15010157.
- 763 9. Sen A, P Pathak, P Shenoy, GM Kohli, P Bhatia,S Shetty. Knowledge, attitude,
764 and practice patterns and the purported reasons for delayed presentation of
765 patients with sight-threatening diabetic retinopathy at a tertiary eyecare facility in
766 Central India: A questionnaire-based study. Indian J Ophthalmol. 2021; 69: p.
767 3118-3122.10.4103/ijo.IJO_1503_21.
- 768 10. Ohlhausen M, C Payne, T Greenlee, AX Chen, T Conti,RP Singh. Impact and
769 Characterization of Delayed Pan-Retinal Photocoagulation in Proliferative
770 Diabetic Retinopathy. Am J Ophthalmol. 2021; 223: p. 267-
771 274.10.1016/j.ajo.2020.09.051.
- 772 11. Gulliford MC, H Dodhia, M Chamley, K McCormick, M Mohamed, S Naithani,
773 et al. Socio-economic and ethnic inequalities in diabetes retinal screening. Diabet
774 Med. 2010; 27: p. 282-8.10.1111/j.1464-5491.2010.02946.x.
- 775 12. Negretti GS, R Amin, L Webster,CA Egan. Does delay in referral of proliferative
776 diabetic retinopathy from the diabetic eye screening programme lead to visual
777 loss? Eye (Lond). 2016; 30: p. 873-6.10.1038/eye.2016.56.
- 778 13. Mozaffarieh M, T Benesch, S Sacu, K Krepler, R Biowski,A Wedrich.
779 Photocoagulation for diabetic retinopathy: determinants of patient satisfaction

- 780 and the patient-provider relationship. *Acta Ophthalmol Scand.* 2005; 83: p. 316-
781 21.10.1111/j.1600-0420.2005.00455.x.
- 782 14. Scanlon PH, ML Martin, C Bailey, E Johnson, P Hykin, S Keightley. Reported
783 symptoms and quality-of-life impacts in patients having laser treatment for sight-
784 threatening diabetic retinopathy. *Diabet Med.* 2006; 23: p. 60-6.10.1111/j.1464-
785 5491.2005.01736.x.
- 786 15. Gorst C, CS Kwok, S Aslam, I Buchan, E Kontopantelis, PK Myint, et al. Long-
787 term Glycemic Variability and Risk of Adverse Outcomes: A Systematic Review
788 and Meta-analysis. *Diabetes Care.* 2015; 38: p. 2354-69.10.2337/dc15-1188.
- 789 16. Sobrin L. Longitudinal validation of hemoglobin A(1c) criteria for diabetes
790 diagnosis: risk of retinopathy. *Diabetes.* 2012; 61: p. 3074-5.10.2337/db12-1226.
- 791 17. Vasiljević JB, IM Kovačević, ZM Bukumirić, GD Marić, NA Slijepčević, TD
792 Pekmezović. Vision-Related Quality of Life and Treatment Satisfaction
793 Following Panretinal Photocoagulation in Diabetic Retinopathy-A Panel Study.
794 *Medicina (Kaunas).* 2022; 58.10.3390/medicina58121741.
- 795 18. Azarcon CP, JCM Artiaga. Comparison of Pain Scores Among Patients
796 Undergoing Conventional and Novel Panretinal Photocoagulation for Diabetic
797 Retinopathy: A Systematic Review. *Clin Ophthalmol.* 2021; 15: p. 953-
798 971.10.2147/opth.S294227.
- 799 19. Fenwick E, G Rees, K Pesudovs, M Dirani, R Kawasaki, TY Wong, et al. Social
800 and emotional impact of diabetic retinopathy: a review. *Clin Exp Ophthalmol.*
801 2012; 40: p. 27-38.10.1111/j.1442-9071.2011.02599.x.

- 802 20. Kaushik M, S Nawaz,TS Qureshi. Profile of sight-threatening diabetic
803 retinopathy and its awareness among patients with diabetes mellitus attending a
804 tertiary care center in Kashmir, India. Indian J Ophthalmol. 2021; 69: p. 3123-
805 3130.10.4103/ijo.IJO_831_21.
- 806 21. Xu L, S Chen, K Xu, Y Wang, H Zhang, L Wang, et al. Prevalence and associated
807 factors of depression and anxiety among Chinese diabetic retinopathy patients: A
808 cross-sectional study. PLoS One. 2022; 17: p.
809 e0267848.10.1371/journal.pone.0267848.
- 810 22. Begum T, A Rahman, D Nomani, A Mamun, A Adams, S Islam, et al. Diagnostic
811 Accuracy of Detecting Diabetic Retinopathy by Using Digital Fundus
812 Photographs in the Peripheral Health Facilities of Bangladesh: Validation Study.
813 JMIR Public Health Surveill. 2021; 7: p. e23538.10.2196/23538.
- 814 23. Jani PD, L Forbes, A Choudhury, JS Preisser, AJ Viera,S Garg. Evaluation of
815 Diabetic Retinal Screening and Factors for Ophthalmology Referral in a
816 Telemedicine Network. JAMA Ophthalmol. 2017; 135: p. 706-
817 714.10.1001/jamaophthalmol.2017.1150.
- 818 24. Scanlon PH. The contribution of the English NHS Diabetic Eye Screening
819 Programme to reductions in diabetes-related blindness, comparisons within
820 Europe, and future challenges. Acta Diabetol. 2021; 58: p. 521-
821 530.10.1007/s00592-021-01687-w.
- 822 25. Pang B, QW Li, YL Qin, GT Dong, S Feng, J Wang, et al. Traditional chinese
823 medicine for diabetic retinopathy: A systematic review and meta-analysis.

- 824 Medicine (Baltimore). 2020; 99: p. e19102.10.1097/md.00000000000019102.
- 825 26. Zhang HW, H Zhang, SJ Grant, X Wan,G Li. Single herbal medicine for diabetic
826 retinopathy. Cochrane Database Syst Rev. 2018; 12: p.
827 Cd007939.10.1002/14651858.CD007939.pub2.
- 828 27. Peterson SR, PA Silva, TJ Murtha,JK Sun. Cataract Surgery in Patients with
829 Diabetes: Management Strategies. Semin Ophthalmol. 2018; 33: p. 75-
830 82.10.1080/08820538.2017.1353817.
- 831 28. Chu CJ, RL Johnston, C Buscombe, AB Sallam, Q Mohamed,YC Yang. Risk
832 Factors and Incidence of Macular Edema after Cataract Surgery: A Database
833 Study of 81984 Eyes. Ophthalmology. 2016; 123: p. 316-
834 323.10.1016/j.opthta.2015.10.001.
- 835 29. Evans JR, M Michelessi,G Virgili. Laser photocoagulation for proliferative
836 diabetic retinopathy. Cochrane Database Syst Rev. 2014; 2014: p.
837 Cd011234.10.1002/14651858.CD011234.pub2.
- 838 30. Bressler SB, WT Beaulieu, AR Glassman, JG Gross, LM Jampol, M Melia, et al.
839 Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes
840 Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology. 2017;
841 124: p. 431-439.10.1016/j.opthta.2016.12.005.
- 842 31. Fallico M, A Maugeri, A Lotery, A Longo, V Bonfiglio, A Russo, et al.
843 Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation
844 and combined treatment for proliferative diabetic retinopathy: a systematic
845 review and network meta-analysis. Acta Ophthalmol. 2021; 99: p. e795-

846 e805.10.1111/aos.14681.

847

848 **Abbreviations:**

AIC	Akaike information criterion
CKD	chronic kidney disease
DR	diabetic retinopathy
HbA1c	glycated hemoglobin level
HTN	hypertension
IV	intravitreal injection
NVI	neovascularization of the iris
NVG	neovascular glaucoma
PDR	proliferative diabetic retinopathy
PRP	pan-retinal photocoagulation
VEGF	vascular endothelial growth factor
VH	vitreous hemorrhage

849 **Acknowledgements**

850 We would like to express our sincere gratitude to all those who contributed to the
 851 successful completion of this study. Their support, guidance, and encouragement have
 852 been invaluable throughout the research process.

853 First and foremost, we extend our heartfelt appreciation to the patients who
 854 participated in this study. Their willingness to share their experiences and insights

855 played a pivotal role in shedding light on the factors contributing to delayed
856 presentation in patients with proliferative diabetic retinopathy.

857 We are grateful to our colleagues and fellow researchers who provided valuable
858 feedback and suggestions during the course of this study. Their expertise greatly
859 enriched the quality of our research.




Figure1